Bayer Schering Pharma AG, Germany, will establish a U.S. Innovation Center in San Francisco, Calif. with the goal to expand its global research network and build its specialty pharmaceutical pipeline.
Original Source of Bayer Schering Pharma Enhances U.S. Research Strategy with New Innovation Center
H. Lundbeck A/S (Lundbeck) announced that the results from the pivotal study with escitalopram in Japan have been received. The results are positive and according to expectations.
Original Source of Positive pivotal results on escitalopram in Japan
Simcere Pharmaceutical Group announced Monday that Chinese officials have imposed a $3.75 million fine on its Jiangsu Yanshen unit as a result of its production of substandard rabies vaccine for humans. According to the decision by
Merck’s ( NYSE: MRK ) decision to end efforts to copy Amgen’s blockbuster Aranesp anemia drug shows how the emerging field of developing generic versions of biotechnology therapies won’t be easy to enter. Report
Original Source of Merck gives up on developing Aranesp copycat
Halozyme Therapeutics is recalling its fluid absorption drug Hylenex and is pointing the finger of blame
GlaxoSmithKline ( NYSE: GSK ) is racing for territory in emerging markets. The pharma giant is aiming to stake its claim in as many markets with as many products as it can–before its rivals do.
Congress has called Johnson & Johnson ( NYSE: JNJ ) CEO Bill Weldon ( photo )
Astellas Pharma and OSI Pharmaceuticals ( NASDAQ: OSIP ) have made nice. Astellas has agreed to buy OSI for $4 billion in cash, or $57.50 per share, in a tender offer beefed up from its original hostile bid of $52. The deal will add OSI’s cancer drug Tarceva to…
Rotavirus vaccines are in the clear. The FDA has decreed that both GlaxoSmithKline’s ( NYSE: GSK ) Rotarix and Merck’s ( NYSE: MRK ) Rotateq are safe despite their contamination with DNA from a pig virus known as porcine circovirus, or PCV. The decision reversed FDA’s stance on Rotarix,…
With all the talk about job cuts this week, we thought we’d leave you with some job creation to mull over the weekend. Merck ( NYSE: MRK )